350 related articles for article (PubMed ID: 19020721)
1. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
2. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder.
Kramer MW; Waalkes S; Serth J; Hennenlotter J; Tezval H; Stenzl A; Kuczyk MA; Merseburger AS
Urol Int; 2011; 87(2):143-50. PubMed ID: 21757871
[TBL] [Abstract][Full Text] [Related]
3. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
4. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
6. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
9. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
12. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
13. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
Pignot G; Bieche I; Vacher S; Güet C; Vieillefond A; Debré B; Lidereau R; Amsellem-Ouazana D
Eur Urol; 2009 Oct; 56(4):678-88. PubMed ID: 18513850
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder.
Ribal MJ; Alcaraz A; Mengual L; Carrio A; Lopez-Guillermo A; Mallofré C; Palou J; Gelabert A; Villavicencio H
Eur Urol; 2004 May; 45(5):593-9. PubMed ID: 15082201
[TBL] [Abstract][Full Text] [Related]
15. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
18. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
20. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
